Rezdiffra (Resmetirom) Max-Dose Rationale: Titration, Escalation, and Beyond

Why Resmetirom Uses Weight-Based Dosing Instead of Gradual Titration

Most drugs in hepatology and endocrinology follow a start-low, go-slow model. Resmetirom does not. The FDA label assigns patients to 80 mg or 100 mg based solely on body weight, with the 100 kg threshold as the dividing line 1. This is a fixed-dose, weight-stratified approach rather than a traditional titration.

The Pharmacokinetic Basis for Weight Stratification

The rationale traces back to resmetirom's pharmacokinetics. Oral bioavailability and volume of distribution scale with body mass. In phase 1 studies, heavier subjects showed lower area-under-the-curve (AUC) values at the same fixed dose 2. Madrigal Pharmaceuticals addressed this by testing two dose tiers in the phase 3 program rather than titrating all patients from a single starting dose.

How MAESTRO-NASH Validated the Two-Tier Model

MAESTRO-NASH randomized 966 adults with biopsy-confirmed MASH and fibrosis stage F1B through F3 to resmetirom 80 mg, resmetirom 100 mg, or placebo 3. Patients weighing under 100 kg received 80 mg; those at or above 100 kg received 100 mg. This was not a dose-finding comparison between 80 mg and 100 mg. Both doses targeted the same therapeutic exposure window in their respective weight bands 4.

The primary endpoints at week 52 were MASH resolution without worsening fibrosis and fibrosis improvement by at least one stage without MASH worsening. In the combined resmetirom group, 25.9% achieved MASH resolution compared to 9.7% on placebo (P<0.001), and 24.2% achieved fibrosis improvement compared to 14.2% on placebo (P<0.001) 3. The consistency across weight-stratified arms confirmed that the two-dose model produced comparable target engagement regardless of body size.

The 100 mg Ceiling: What the Evidence Actually Supports

The maximum labeled dose of Rezdiffra is 100 mg once daily. There is no approved 120 mg, 150 mg, or any supratherapeutic dose 1. This ceiling was not arbitrary.

Phase 2 Dose-Ranging Data

In the earlier phase 2 trial (N=125), resmetirom 80 mg daily reduced hepatic fat fraction by a relative 32.9% at 36 weeks versus placebo, measured by MRI-proton density fat fraction (MRI-PDFF) 5. The dose-response curve suggested diminishing marginal returns above exposures corresponding to 100 mg, with rising thyroid hormone-mediated side effects (diarrhea, nausea) at higher plasma concentrations. Madrigal selected the 80/100 mg weight-based strategy to stay within the therapeutic window where liver-selective THR-β activation outpaced systemic thyroid effects 6.

THR-β Selectivity and the Safety Margin

Resmetirom achieves roughly 28-fold selectivity for THR-β over THR-α 7. THR-α mediates cardiac and bone effects of thyroid hormone. Pushing beyond 100 mg risks narrowing this selectivity margin. Animal models showed dose-dependent increases in heart rate and bone turnover markers when THR-β selectivity was overcome at higher exposures 7. The FDA's pharmacology review explicitly cited this selectivity ratio as a factor in dose ceiling determination 4.

No published clinical data support resmetirom use above 100 mg daily in humans. Off-label supratherapeutic dosing is not recommended by any professional society, including the American Association for the Study of Liver Diseases (AASLD) 8.

How to Start Rezdiffra: Day-One Dosing Protocol

Prescribers do not need to uptitrate resmetirom. The process is straightforward.

Step 1: Confirm Eligibility

The FDA indication is limited to adults with noncirrhotic MASH and moderate to advanced hepatic fibrosis (stages F2-F3) 1. Diagnosis requires liver biopsy or a validated noninvasive test consistent with at-risk MASH. The AASLD practice guidance endorses FibroScan (vibration-controlled transient elastography) with a liver stiffness measurement ≥8 kPa as a reasonable noninvasive screening threshold for significant fibrosis 8.

Step 2: Weigh the Patient

Body weight determines the dose. Under 100 kg: prescribe 80 mg once daily. At or above 100 kg: prescribe 100 mg once daily 1. Reweigh at follow-up visits. If a patient's weight crosses the 100 kg threshold in either direction, adjust the dose accordingly.

Step 3: Baseline Labs

Before starting, obtain a comprehensive metabolic panel, lipid panel, and thyroid function tests (TSH, free T4). The label warns about potential gallbladder-related adverse events, and baseline hepatic function helps distinguish drug effect from disease progression 1. The Endocrine Society recommends thyroid function monitoring in patients receiving any THR-active agent 9.

Step 4: Dispense and Counsel

Resmetirom is taken once daily, with or without food. No loading dose. No taper-in period. Counsel patients about the most common adverse reactions from MAESTRO-NASH: diarrhea (27.3% vs 18.5% placebo) and nausea (22.2% vs 13.5% placebo) 3. These GI effects typically present in the first four weeks and diminish with continued use.

Monitoring After Dose Assignment

Because there is no gradual escalation, the monitoring schedule focuses on safety surveillance and treatment response rather than dose adjustment.

Hepatic and Thyroid Surveillance

The FDA label recommends periodic monitoring of liver tests 1. Most hepatologists check ALT, AST, and bilirubin at weeks 4, 12, and 24 after initiation, then every six months. TSH should be checked at 4 to 8 weeks after starting, then at 6-month intervals 9. In MAESTRO-NASH, resmetirom reduced TSH levels modestly (mean decrease of approximately 20% from baseline), reflecting its thyromimetic activity at the pituitary, though clinical hypothyroidism was rare 3.

Lipid Panel Changes

Resmetirom produced a 16% reduction in LDL cholesterol and a 20% reduction in apolipoprotein B at 52 weeks in MAESTRO-NASH 3. These changes may affect statin dosing decisions. A lipid panel at 12 weeks post-initiation helps guide any necessary adjustments to concurrent dyslipidemia therapy. The 2018 AHA/ACC cholesterol guideline provides the framework for integrating these changes into overall cardiovascular risk management 10.

Gallbladder Monitoring

The Rezdiffra label carries a warning about cholelithiasis. In clinical trials, gallbladder-related events (including cholecystitis and cholelithiasis) occurred more frequently in resmetirom-treated patients than placebo 1. Patients with known gallstones or prior cholecystectomy should be counseled, and clinicians should maintain a low threshold for right-upper-quadrant imaging if symptoms arise.

What Happens When 100 mg Is Not Enough

Some patients will not achieve histological response at the labeled maximum. MAESTRO-NASH showed that roughly 74% of treated patients did not meet the primary endpoint of MASH resolution at 52 weeks 3. This is consistent with the heterogeneity of MASH pathophysiology.

Combination Therapy Approaches

The field is moving toward combination strategies rather than dose escalation beyond 100 mg. A GLP-1 receptor agonist added to resmetirom targets the metabolic and inflammatory axes that THR-β agonism alone may not fully address. Semaglutide 2.4 mg showed independent histological benefit in MASH in a phase 2 trial (N=320), with 59% achieving MASH resolution at 72 weeks versus 17% on placebo 11. Preclinical and early clinical data suggest additive effects when THR-β agonists are paired with GLP-1RAs, given their non-overlapping mechanisms 12.

Ongoing Trials Exploring Expanded Dosing

MAESTRO-NAFLD-1 (NCT04197479) enrolled a broader population including patients with NAFLD/MASLD without advanced fibrosis and collected 52-week safety and cardiovascular biomarker data 13. MAESTRO-NASH itself included a 24-month extension evaluating durability. Neither trial tested doses above 100 mg. As of mid-2026, no registered trial on ClinicalTrials.gov evaluates resmetirom above 100 mg daily 14.

The absence of dose-escalation trials above 100 mg reflects both the THR-β selectivity ceiling and the pivot toward combination regimens as the preferred strategy for non-responders.

Dose Adjustments in Special Populations

Hepatic Impairment

Resmetirom is not recommended in patients with decompensated cirrhosis (Child-Pugh B or C) 1. In compensated cirrhosis (Child-Pugh A), the label does not specify dose modification, but the drug was studied primarily in F2-F3 fibrosis. Clinicians treating patients with early cirrhosis (F4 without decompensation) should weigh the limited data against potential benefit 8.

Renal Impairment

No dose adjustment is required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²). Resmetirom has not been studied in severe renal impairment or dialysis 1.

Drug Interactions

Resmetirom is a weak inducer of CYP2B6 and a moderate inhibitor of OATP1B1/1B3 transporters. Concomitant use with drugs that are sensitive OATP1B1 substrates (such as certain statins) may increase their plasma concentrations 1. Given that many MASH patients take statins, this interaction demands attention at initiation. The FDA drug interaction guidance recommends monitoring for myopathy symptoms when combining resmetirom with rosuvastatin or pitavastatin 15.

Weight Changes and Dose Reassignment Over Time

Patients with MASH frequently lose weight during treatment, whether from resmetirom's metabolic effects, concurrent GLP-1RA use, or lifestyle modification. A patient who starts at 105 kg on the 100 mg dose and drops below 100 kg should be reassessed.

The label does not mandate switching to 80 mg when weight decreases below the threshold. Clinical judgment applies. If the patient tolerates 100 mg without adverse effects and maintains therapeutic benefit, many hepatologists will continue the current dose. If GI side effects emerge or TSH suppression becomes clinically significant, stepping down to 80 mg is reasonable 1. The same logic applies in reverse: weight gain above 100 kg on the 80 mg dose warrants reassessment and potential escalation to 100 mg.

Comparing Resmetirom Dosing to Other MASH Therapies

Resmetirom's fixed weight-based model contrasts with the gradual titration required for most GLP-1RAs. Semaglutide (Wegovy) requires a 16-week escalation from 0.25 mg to 2.4 mg weekly 16. Tirzepatide (Zepbound) follows a similar stepwise ramp over 20 weeks 17. These prolonged titrations exist because GLP-1RA GI tolerability is dose-limiting and requires gradual receptor desensitization.

Resmetirom does not require this runway. GI side effects in MAESTRO-NASH were front-loaded in the first month and generally self-limiting, without the need for a multi-week dose ramp 3. For clinicians managing patients who need both a THR-β agonist and a GLP-1RA, this means resmetirom can reach full therapeutic exposure while the GLP-1RA is still being titrated.

The 2023 AASLD practice guidance positions resmetirom as a first-line pharmacotherapy option for at-risk MASH with F2-F3 fibrosis, alongside lifestyle intervention 8. Pioglitazone and vitamin E remain alternatives for patients who cannot access or tolerate resmetirom, though neither achieved conditional FDA approval for MASH 18.

Resmetirom 100 mg once daily represents the dose ceiling supported by current evidence. Exceeding it risks losing the THR-β selectivity advantage. For non-responders, combination therapy is the path forward, not dose escalation.